Eptinezumab for treating a migraine attack right now
Part of Brain & nervous system, Pain clinical trials.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have migraine with or without aura, or chronic migraine, diagnosed by a doctor.
- You have at least 8 migraine days per month.
- You must be able to follow study rules and keep a migraine diary for at least one month.
- You are currently having a migraine attack when the medicine is given.
- You are already enrolled in the TACHIS study (NCT06409845).
- You are not pregnant or breastfeeding, and you haven't changed your migraine prevention medicine in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
This trial tests whether a medication called rimegepant can prevent migraines when you take it before a known trigger (like exercise or stress). It is for people who get migraines often and can predict when one might happen.
This study tests an investigational medicine called elismetrep (K-304) for treating migraine attacks quickly. If you have migraines, you take the medicine when a migraine starts and report how well it works.
This study tests how well a new acute migraine medicine, zavegepant, works and is tolerated in people who are already taking a CGRP-targeting preventive medication. It may help you find an effective treatment when you get a migraine attack.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.